Literature DB >> 17878677

Characterization of follistatin-related gene as a negative regulatory factor for activin family members during mouse heart development.

Yuka Takehara-Kasamatsu1, Kunihiro Tsuchida, Masashi Nakatani, Tatsuya Murakami, Akira Kurisaki, Osamu Hashimoto, Hideyo Ohuchi, Hitomi Kurose, Kazuhiro Mori, Shoji Kagami, Sumihare Noji, Hiromu Sugino.   

Abstract

Follistatin-related gene (FLRG) encodes a secretory glycoprotein that has characteristic cysteine-rich follistatin domains. FLRG protein binds to and neutralizes several transforming growth factor-beta (TGF-beta) superfamily members, including myostatin (MSTN), which is a potent negative regulator of skeletal muscle mass. We have previously reported that FLRG was abundantly expressed in fetal and adult mouse heart. In this study, we analyzed the expression of FLRG mRNA during mouse heart development. FLRG mRNA was continuously expressed in the embryonic heart, whereas it was very low in skeletal muscles. By contrast, MSTN mRNA was highly expressed in embryonic skeletal muscles, whereas the expression of MSTN mRNA was rather low in the heart. In situ hybridization and immunohistochemical analysis revealed that FLRG expressed in smooth muscle of the aorta and pulmonary artery, valve leaflets of mitral and tricuspid valves, and cardiac muscles in the ventricle of mouse embryonic heart. However, MSTN was expressed in very limited areas, such as valve leaflets of pulmonary and aortic valves, the top of the ventricular and atrial septa. Interestingly, the expression of MSTN was complementary to that of FLRG, especially in the valvular apparatus. Biochemical analyses with surface plasmon resonance biosensor and reporter assays demonstrated that FLRG hardly dissociates from MSTN and activin once it bound to them, and efficiently inhibits these activities. Our results suggest that FLRG could function as a negative regulator of activin family members including MSTN during heart development.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17878677     DOI: 10.2152/jmi.54.276

Source DB:  PubMed          Journal:  J Med Invest        ISSN: 1343-1420


  10 in total

1.  Characterization of follistatin-type domains and their contribution to myostatin and activin A antagonism.

Authors:  Jennifer N Cash; Elizabeth B Angerman; Henry T Keutmann; Thomas B Thompson
Journal:  Mol Endocrinol       Date:  2012-05-16

Review 2.  Inhibin at 90: from discovery to clinical application, a historical review.

Authors:  Yogeshwar Makanji; Jie Zhu; Rama Mishra; Chris Holmquist; Winifred P S Wong; Neena B Schwartz; Kelly E Mayo; Teresa K Woodruff
Journal:  Endocr Rev       Date:  2014-07-22       Impact factor: 19.871

Review 3.  Activins and Inhibins: Roles in Development, Physiology, and Disease.

Authors:  Maria Namwanje; Chester W Brown
Journal:  Cold Spring Harb Perspect Biol       Date:  2016-07-01       Impact factor: 10.005

4.  Structure of myostatin·follistatin-like 3: N-terminal domains of follistatin-type molecules exhibit alternate modes of binding.

Authors:  Jennifer N Cash; Elizabeth B Angerman; Chandramohan Kattamuri; Kristof Nolan; Huaying Zhao; Yisrael Sidis; Henry T Keutmann; Thomas B Thompson
Journal:  J Biol Chem       Date:  2011-11-03       Impact factor: 5.157

Review 5.  TGF-β Family Signaling in Early Vertebrate Development.

Authors:  Joseph Zinski; Benjamin Tajer; Mary C Mullins
Journal:  Cold Spring Harb Perspect Biol       Date:  2018-06-01       Impact factor: 10.005

6.  Myostatin represses physiological hypertrophy of the heart and excitation-contraction coupling.

Authors:  Buel D Rodgers; Jillian P Interlichia; Dilip K Garikipati; Ranganath Mamidi; Murali Chandra; O Lynne Nelson; Charles E Murry; Luis F Santana
Journal:  J Physiol       Date:  2009-09-07       Impact factor: 5.182

7.  Chromosome 19p13.3 deletion in a child with Peutz-Jeghers syndrome, congenital heart defect, high myopia, learning difficulties and dysmorphic features: Clinical and molecular characterization of a new contiguous gene syndrome.

Authors:  Josiane Souza; Fábio Faucz; Vanessa Sotomaior; Aguinaldo Bonalumi Filho; Jill Rosenfeld; Salmo Raskin
Journal:  Genet Mol Biol       Date:  2011-10-01       Impact factor: 1.771

8.  Discovery of a mammalian splice variant of myostatin that stimulates myogenesis.

Authors:  Ferenc Jeanplong; Shelley J Falconer; Jenny M Oldham; Mark Thomas; Tarra S Gray; Alex Hennebry; Kenneth G Matthews; Frederick C Kemp; Ketan Patel; Carole Berry; Gina Nicholas; Christopher D McMahon
Journal:  PLoS One       Date:  2013-12-02       Impact factor: 3.240

9.  Embryonic Lethality Due to Arrested Cardiac Development in Psip1/Hdgfrp2 Double-Deficient Mice.

Authors:  Hao Wang; Ming-Chieh Shun; Amy K Dickson; Alan N Engelman
Journal:  PLoS One       Date:  2015-09-14       Impact factor: 3.240

10.  Peptide-2 from mouse myostatin precursor protein alleviates muscle wasting in cancer-associated cachexia.

Authors:  Chiharu Ojima; Yuri Noguchi; Tatsuki Miyamoto; Yuki Saito; Hiroki Orihashi; Yasuhiro Yoshimatsu; Tetsuro Watabe; Kentaro Takayama; Yoshio Hayashi; Fumiko Itoh
Journal:  Cancer Sci       Date:  2020-07-01       Impact factor: 6.716

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.